This study aims to evaluate the effectiveness of levodopa
as a therapeutic drug in the treatment of children and adults with amblyopia
We performed a systematic review and meta-analysis
with randomized controlled trials of levodopa
and placebo in the treatment of amblyopia
. All data were identified and extracted from the PubMed, EMBASE, Cochrane libraries, and the Chinese knowledge resource integration database.
After screening the literature and evaluating the quality, 11 studies met the criteria from 308 studies. The mean difference of LogMAR visual acuity
and the placebo group was −0.1031 (95% confidence interval, −0.11 to −0.09; P
< 0.0001). The improvement of visual acuities of the subgroup of younger patients with amblyopia
was significantly higher than that of the placebo group (P
< 0.0001). Increasing the dosage of levodopa
and prolonging the treatment can significantly improve the curative effect.
is effective in the treatment of amblyopia
by prolonging the treatment, especially for young patients.